A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal
{"title":"转移性肾细胞癌的最佳一线治疗:网络荟萃分析","authors":"A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal","doi":"10.3233/KCA-180032","DOIUrl":null,"url":null,"abstract":"Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-180032","citationCount":"1","resultStr":"{\"title\":\"Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis\",\"authors\":\"A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal\",\"doi\":\"10.3233/KCA-180032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon\",\"PeriodicalId\":17823,\"journal\":{\"name\":\"Kidney Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2018-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3233/KCA-180032\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/KCA-180032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/KCA-180032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis
Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
